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Purpose: High glucose level in diabetic patients may lead to advanced glycation end product (AGE) modified proteins.
This study investigated AGE modified proteins in tears and compared their levels in diabetic patients (DM) with non-
diabetic controls (CTL).
Methods: Basal tears were collected from DM with (DR) or without (DNR) retinopathy and CTL. Total AGE modified
proteins were detected quantitatively by a dot immunobinding assay. The AGE modified proteins were separated in 1D-
and 2D-SDS gels and detected by western-blotting. The individual AGE modified proteins were also compared between
groups using densitometry.
Results: Compared with the CTL group, tear concentrations of AGE modified proteins were significantly elevated in DR
and DNR groups. The concentration of AGE modified proteins in diabetic tears were positively correlated with AGE
modified hemoglobin (HbA1c) and postprandial blood glucose level (PBG). Western blotting of AGE modified proteins
from 1D-SDS gels showed several bands, the major one at around 60 kDa. The intensities of AGE modified protein bands
were higher in DM tears than in CTL tears. Western blotting from 2D-SDS gels showed a strongly stained horizontal strip,
which corresponded to the major band in 1D-SDS gels. Most of the other AGE modified protein species were within
molecular weight of 30–60 kDa, PI 5.2–7.0. Densitometry analysis demonstrated several AGE modified proteins were
elevated in DR or DNR tears.
Conclusions: Total and some individual AGE modified proteins were elevated in DM tears. AGE modified proteins in
tears may be used as biomarkers to diagnose diabetes and/or diabetic retinopathy.
The human tear fluid has a complex multilayered film
structure [1]. Although up to six layers have been proposed,
most  researchers  agree  that  some  form  of  three-layered
structure  is  probably  operational  in  the  normal  eye,
comprising an extensive aqueous layer situated between a
mucin  layer  and  a  lipid  layer  [2,3].  Maintenance  of  this
structure is important in performing tear film function and
minimizing tear fluid evaporation [4,5]. The aqueous layer,
which is mainly secreted from the lacrimal gland, contains
locally synthesized and other sources, such as serum, derived
proteins  [6,7].  Quantitatively,  the  major  tear  proteins  are
lysozyme, tear lipocalin, secretory immunoglobulin A (sIgA),
and lactoferrin [8]. Nearly 500 other less abundant proteins
have also been reported in human tear fluid [9-11].
One of the fundamental functions of human tear film is
to protect the cornea and conjunctiva and keep them healthy.
Protein components are vital in achieving this goal [12]. To
help prevent corneal or conjunctival infection, tear proteins
such  as  lactoferrin,  lysozyme  and  complement  proteins
comprise the non-adaptive antimicrobial factors, and sIgA
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comprises the predominant adaptive protein [13]. Other tear
proteins such as tear lipocalin, a lipid-binding protein in tears,
may help stabilize the tear film [14,15]. Tear proteins have
other functions such as promoting wound healing [16] by
affecting  the  migration  of  ocular  surface  epithelial  cells.
Bioactive proteins and peptides such as cytokines have also
been detected in tears and they may participate in regulating
the biochemical processes inside corneal and conjunctival
epithelial cells [10,17].
Studies have demonstrated that glucose exists in tears and
its  level  is  elevated  in  diabetic  (DM)  patients  [18,19].  In
theory, tear proteins, especially those derived from blood or
ocular surface epithelial cells with a long half-life in the body,
could  undergo  glycation  (non-enzymatic  glycosylation)  in
this pathological condition [20] due to a spontaneous sugar
concentration-dependent chemical (non enzymatic) reaction
of  reducing  sugars  with  the  amino  groups  of  proteins.
Glycation results in the production of advanced glycation end
product (AGE) modified proteins which might impair protein
function.  In  addition,  AGE  modified  proteins  have  been
reported to participate in many DM complications [21,22],
including diabetic retinopathy (DR) [23,24]. Increased level
of these proteins in tears may be an indicator of retina damage
and also may affect the ocular surface. To the best of our
knowledge,  there  is  no  report  regarding  AGE  modified
proteins in tears, although AGE modified proteins in blood
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1576[25,26] and other organs [27-32] have been the subject of
many  previous  studies,  and  AGE  modified  hemoglobin
(HbA1c) has been used to monitor DM for many years [33].
The eye is very sensitive to high blood glucose levels.
DR, the most frequent diabetic microvascular disease, is the
most frequent cause of new cases of blindness among adults
aged 20–74 years [34]. During the first two decades of disease,
nearly all patients with type 1 DM and >60% of patients with
type  2  DM  develop  DR  [34].  The  ocular  surface  can  be
affected  by  DM  and  reduced  corneal  sensitivity  [35]  and
altered tear quantity and quality are observed in DM patients
[36].  Dry  eye  syndrome,  an  ocular  surface  disease,  is
frequently found in DM patients, and a positive correlation
was found between HbA1c level and the presence of dry eye
syndrome [37].
As the first step to elucidate the effect of AGE modified
proteins on diabetic eye complications, we analyzed AGE
modified proteins in tears from DM patients with or without
retinopathy.
METHODS
Study  subjects:  All  subjects  were  recruited  from  the
Department  of  Endocrinology,  First  Hospital  Affiliated,
Medical School of Xi’an Jiaotong University, Xi'an, China.
DM  was  diagnosed  according  to  the  1999  World  Health
Organization  criteria.  DR,  including  non-proliferative  DR
(NPDR) and proliferative DR (PDR), was defined on the basis
of fundus examination and fluorescein angiography. NPDR is
characterized  by  microaneurysm,  hemorrhage,  exudate,
macular ischemia, macular edema on the retina, and PDR
characterized by abnormal new vessel formation on the retina,
vitreous hemorrhage, and traction retinal detachment.
Forty-eight  type  2  DM  patients  without  retinopathy
(DNR), 49 patients with retinopathy (DR) and 50 sex- and
age-matched non-DM controls (CTL) were recruited. Due to
the small amount of tears that can be collected, samples in
each group were randomly separated into three subgroups,
i.e.,  tears  for  dot-immunobinding  assay,  tears  for  one-
dimensional (1D) gel analysis, and tears for two-dimensional
(2D) gel analysis, respectively (see below, Table 1). Test
results of fasting blood glucose (FBG), postprandial blood
glucose  (PBG),  and  HbA1c  levels,  measured  by  standard
procedures used in pathology laboratories, were collected for
all DM patients. Patients’ age, gender and duration of diabetes
were recorded. Student’s t-test showed that there were no
significant differences between DNR and DR groups for any
of the parameters except for diabetic duration in the 2D gel
analysis subgroup (Table 1).
Before enrolment in the study, all subjects signed an
informed consent after explanation of the nature and possible
consequences of the study. All experimental protocols were
reviewed and approved by the hospital Human Ethics Review
Committee and complied with the Declaration of Helsinki for
Experimentation on Humans, 1975 and revised in 1983.
TABLE 1. CLINICAL CHARACTERISTICS OF THE DIABETIC PATIENTS AND NON-DIABETIC CONTROLS.
Group
Age
(years)
Sex
(M/F)
Diabetes
duration
(years)
FBG
(mmol/l)
PBG
(mmol/l)
HbA1c
(%)
Samples used in dot immunobinding assay
CTL 59.0±9.4 8/7 - - - -
DR 61.3±7.6 7/8 8.0±6.8 9.1±2.4 12.4±3.7 10.0±2.4
DNR 61.1±8.4 8/7 9.0±4.5 7.7±3.4 11.8±4.2 9.9±2.6
Samples used in 1D gel analysis
CTL 54.4±12.0 3/2 - - - -
DR 64.5±5.0 2/2 9.8±9.4 8.2±1.5 10.4±1.7 8.0±2.6
DNR 68.5±5.0 1/2 8.5±0.7 7.9±1.0 10.4±1.0 7.0±0.9
Samples used in 2D gel analysis
CTL 57.3±8.6 15/15 - - - -
DR 59.1±10.6 15/15 11.0±6.1 9.4±2.8 14.1±5.5 10.0±2.3
DNR 57.3±11.2 15/15 5.9±4.6* 9.7±3.7 15.6±6.8 9.8±2.8
In the table, CTL: non-diabetic controls; DR: type 2 diabetics with retinopathy; DNR: type 2 diabetics without retinopathy;
FBG: fast  blood glucose; PBG: postprandial blood glucose; HbA1c: glycosylated hemoglobin. Data were expressed as mean
±standard deviation. The asterisk indicates a p<0.01.
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1577Tear samples: Open eye basal tear samples were collected by
a blunt glass capillary tube to obtain 5–10 µl tears from the
outer canthus of the eye. Total protein concentration of each
sample was assayed using a Lavapep protein quantification
kit (Fluorotechnics, Gladesville, NSW, Australia) according
to  the  manufacturer’s  instruction.  The  tear  samples  were
stored at −80 °C until tested.
Dot-immunobinding  assay  of  AGE  modified  proteins:
Aliquots of the tear samples were diluted 1:20 in PBS (pH
7.4).  Four  µl  of  the  diluted  tear  samples  and  various
concentrations  of  glycated  BSA  (AGE-BSA;  Sapphire
Bioscience,  Redfern,  NSW,  Australia)  were  dotted  on
nitrocellulose (NC) membrane at 1 cm intervals and allowed
to dry for 1 h at ambient temperature (AT). Unreacted protein-
binding sites on the membrane were blocked by immersing
the membranes in 3% BSA in Tris-buffer saline (TBS, 10 mM
Tris base and 150 mM NaCl, pH 7.5) and incubated for 2 h at
AT, followed by washing three times with 0.05% Tween-20
in TBS (TBST). NC membranes were incubated with rabbit
anti-human AGE polyclonal antibody (Sapphire Bioscience,
Redfern, NSW, Australia) diluted 1:1,000 in blocking solution
containing 0.5% BSA (BMBA) for 2 h at AT. After washing
three times with TBST, the membrane was incubated with
secondary antibody (goat anti-rabbit IgG peroxidase-labeled;
Bio-Rad, Hercules, CA) diluted 1:10,000 in BMBA for 1 h at
AT.  Luminal/enhance  and  peroxidase  buffer  solutions
(Immun Star WesternC Kit 170–5070; Bio-Rad) in a 1:1 ratio
were added to the membrane after another three washes and
incubated for 3–5 min. The chemiluminescent spots were
detected  using  a  Versa  Doc  Imaging  System  (Bio-Rad).
Quantity-one software (Bio-Rad) was used to analyze the
image. Standard curves were generated using the AGE-BSA
standards (1,000, 500, 250, 125, 62.5, 31.2 and 15.6 ng/ml)
and  were  used  to  calculate  the  concentrations  of  AGE
modified  proteins  in  tear  samples.  The  results  were  also
divided by total protein concentration to convert to amount
(µg) of AGE modified proteins per mg of total tear proteins.
The antigen to which this polyclonal-AGE antibody was
raised  was  a  proprietary  mixture  of  AGE-human  serum
albumin  and  AGE-BSA  (Abcam,  product  datasheet).  The
antibody reacts with several different AGE moieties, such as
Nε-(carboxymethyl)lysine, imidazolone and others, but has
minimal reactivity (<1%) to purified HSA and BSA (product
datasheet).
Western-blotting detection of AGE modified proteins in 1D-
SDS gels: Three µl tear samples (20–30 μg total protein) were
mixed with 1 µl of 4× sample buffer (0.125 M Tris-HCl, 2%
SDS, 40% v/v glycerol, 0.8% bromophenol blue, pH 6.8).
Following incubation at AT for 10 min, samples were loaded
onto a pre-cast Bio-Rad 4%–12% Bis-Tris 1.0 mm minigel.
Electrophoresis was performed at 100 V in running buffer
(25 mM Tris base, 0.1% SDS, 192 mM glycine, pH 8.3) until
the dye front reached the end of the gel. After soaking the gel
in equilibrating buffer (25 mM Tris base, 192 mM glycine,
20% methanol, pH 8.3) for 30 min, the proteins were electro-
transferred  to  NC  membrane  using  a  Bio-Rad  mini-gel
transfer apparatus in transfer buffer (250 mM Tris base, 1.92
M glycine, 20% methanol, pH 8.3) at 100 V, 4 °C for 1 h. The
membrane was washed twice in MilliQ water, then blocked
for 2 h with protein-free blocking buffer (Quantum Scientific,
Murarrie,  Queensland,  Australia)  at  AT.  Following  three
rinses with TBST, the membrane was incubated with rabbit
anti-human AGE polyclonal antibody, goat anti-rabbit IgG
(diluted  1:  40,000  in  protein-free  blocking  buffer)  and
substrate  as  in  dot-immunobinding  assay.  Bands  were
visualized and analyzed as described above. The membranes
were stained with Ponceau S, a general protein staining dye,
after western blotting to visualize the major proteins in tears.
Western-blot detection of AGE modified proteins in 2D-SDS
gels: Since the protein amount in a single sample was not
enough to run a 2D gel, tears from age- and gender-matched
subjects in each group were pooled into three samples to
obtain sufficient quantities of each sample for 2D gel analysis.
Total  protein  concentration  of  the  pooled  samples  was
detected using the Lavapep protein quantitation kit according
to the manufacturer’s instruction.
Two  gels  were  run  simultaneously  for  each  pooled
sample, one (loaded with 60 μg of tear protein) for western
blotting  detection  of  AGE  modified  proteins  and  another
(loaded with 250 μg of tear protein) for Sypro Ruby staining
of all tear proteins. Tear samples were mixed with 80 μl and
120 μl IEF sample buffer (MiPrep MTM ; Minomic Pty Ltd,
Sydney, Australia) respectively. An 11 cm IPG strip pH 4–7
(Readystrips;  Bio-Rad)  was  rehydrated  in  200  μl  MiPrep
MTM for 5–6 h. Then cup loading of all samples was performed
using two cups, which were placed at the cathode and anode
ends  of  the  strip,  each  containing  half  the  amount  of  the
sample.  IEF  was  run  at  100  μA/strip  at  24  °C  using  an
IPGphore (GE Healthcare, Uppsala, Sweden) until a total Vh
of at least 50,000 was reached. Strips were reduced for 15 min
in 6 M urea, 2% SDS, 0.375 M Tris, 50% glycerol, 100 mM
DTT, pH 8.8 and then alkylated for 15 min in 6 M urea, 2%
SDS, 0.375 M Tris, 50% glycerol, 2.5% acrylamide, pH 8.8
at AT. The second dimension was run using Bio-Rad Criterion
8%–16% gels at 4 °C, 200 V for 1 h. Five μl of precision Plus
ProteinTM  unstained  molecular  weight  markers  (Bio-Rad)
were loaded in every gel at the cathode end. For all tear protein
staining, the gels (250 μg total protein) were fixed in 7% acetic
acid and 10% ethanol, stained overnight in Sypro Ruby (Bio-
Rad) and then destained in 7% acetic acid and 10% ethanol
before imaging using a proXpress CCD imager (excitation
480 nm, emission 620 nm; PerkinElmer Life and Analytical
Sciences,  Boston,  MA).  For  specific  western  blotting
detection, proteins from the gel (60 μg total protein) were
transferred to NC membrane and then AGE modified proteins
detected using anti-AGE antibody as described above.
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was  performed  using  Progenesis  SameSpots  2.0  software
(Nonlinear Dynamics Limited, Newcastle upon Tyne, UK).
The  process  included  SameSpots  detection,  background
subtraction,  normalization  and  matching.  Matching  of  the
spots was performed using automated image alignment with
manual  adjustment.  Differences  in  levels  of  protein
expression between the three groups were analyzed by one-
way  ANOVA.  Differences  were  considered  significant  at
p<0.05.
RESULTS
Dot-immunobinding assay of total AGE modified proteins in
tears: Fifteen tear samples from each group were analyzed by
dot-immunobinding  assay  using  anti-AGE  antibody.  The
images of tears from CTL, DNR and DR patients are shown
in Figure 1. Based on the dot intensity of the standard AGE
modified BSA, the amount of total AGE modified proteins in
each tear sample was calculated (Table 2). Compared with the
CTL group, tear concentrations of AGE modified proteins
were elevated in DR and NDR groups. Concentrations of AGE
modified proteins were higher in DR group than DNR group
but  the  difference  did  not  achieve  statistical  significance
(p>0.05). After converting the results to μg AGE modified
proteins per mg tear protein, the two DM groups still had
higher amount of AGE modified proteins but the statistical
difference  between  CTL  and  DNR  became  insignificant,
whereas CTL versus DR remained significantly different.
Correlation  of  total  AGE  modified  proteins  and  clinical
parameters: Simple liner regression analysis showed that in
these patient subgroups, the concentration (μg/ml) of AGE
modified proteins in tears were positively correlated with
HbA1c (r=0.420, p=0.021) and PBG (r=0.366, p=0.046) in
diabetic patients (Figure 2), but no association was found
between  AGE  modified  protein  concentration  and  FBG.
However no correlation was found with any of the clinical
parameters after converting the results to µg/mg tear proteins.
Western-blotting analysis of AGE modified proteins in 1D-
SDS gels: A further set of tear samples, 3–5 in each group,
was separated in 1D-SDS gels and AGE modified proteins
were detected using anti-AGE antibody after transferring to
Figure 1. Images of dot-immunobinding
assay of total AGE modified proteins in
tears from DR, DNR, and CTL subjects.
One dot represented a tear sample from
a subject. The left lane was the AGE-
BSA standard in various amounts.
TABLE 2. QUANTIFICATION OF AGE MODIFIED PROTEINS IN TEARS.
  AGE modified proteins
Group µg/ml tears µg/mg tear protein
CTL 3.28±1.96* 0.36±0.21**
DR 7.68±3.31 0.68±0.44
DNR 5.80±2.80 0.45±0.25
The asterisk indicates a p<0.05 versus DR and DNR, and the double asterisk indicates a p<0.05 versus DR.
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1579NC membranes. Representative images of the blotting of three
tear samples, one from each of the groups, are shown in Figure
3. Consistent with the dot immunobinding assay, more and
stronger AGE modified protein bands could be seen in the tear
samples  of  DM  with  or  without  retinopathy  than  CTL
samples, indicating more proteins were AGE modified and the
modification was higher in DM tears. A major band with a
molecular weight (MW) of around 60 kDa appeared in every
gel. A weak band approximately at the position of 13 kDa was
also visible in DM tears. Ponceau S staining of the membrane
detected three major tear proteins that probably corresponded
to lactoferrin (A), tear lipocalin (B) and lysozyme (C) [38].
Similar intensities of the major tear protein bands stained by
Ponceau S in each of the samples (image not shown) indicated
Figure 2. Correlation of tear total AGE modified proteins and HbA1c and PBG in DM patients with or without retinopathy.
Figure 3. 1D western blotting images of
AGE modified tear proteins from DR,
DNR, and CTL samples. PS: a Ponceau
S stained tear proteins on the blot. A:
lactoferrin,  B:  tear  lipocalin,  C:
lysozyme.
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1580that the higher amount of AGE modified proteins in DM tears
was not due to larger amount of total proteins in the samples.
No AGE-stained bands in the blot corresponded to probably
location of tear lipocalin, indicating that this major protein
was not AGE modified.
A NDR tear sample was used to do this western blotting
detection without anti-AGE antibody. No band was detected
in the membrane, indicating that the positive staining was not
due to unspecific binding of the second antibody (goat anti-
rabbit IgG) to some proteins in tears (image not shown).
Western-blotting analysis of AGE modified proteins in 2D-
SDS gels: The western blot of the 2D gels showed many spots
in every sample, indicating that many protein species were
potentially  AGE  modified,  even  in  CTL  tears  (Figure  4).
Compared to CTL tears, DM tears (DR and DNR) again were
demonstrated to contain more AGE modified protein species.
The locations of the AGE modified protein spots were very
different from the location of tear protein spots in 2D gels
stained with Sypro Ruby, indicating that most of the glycated
proteins were of low abundance and not detectable by Sypro
Ruby staining. A long strongly stained horizontal strip, which
corresponded  to  the  major  band  in  1D  gels,  at  MW  of
approximately  60  kDa  and  PI  of  4.5–6.2  appeared  in  all
samples. Most of the other AGE modified protein species
were within a range of molecular weight 30–60 kDa, PI 5.2–
7.0 (Figure 4). The patterns of AGE modified protein staining
were similar in all the tear samples but varied in intensity.
Image analysis showed that many spots were upregulated
in DR tears or DNR tears when compared with CTL tears
(Figure 5). This was most obvious for spot 18. Taking CTL
tears as a reference, its intensity increased 7.4 fold and 3.1 fold
in DR and DNR tears, respectively. The intensity of spot 5
increased 4.1 fold in DR tears but did not increase in DNR
tears. Conversely, the intensity of spot 35 was elevated 2.9
fold  in  DNR  tears  but  did  not  change  in  DR  tears.  No
significant  differences  were  detected  for  spot  intensities
between DNR group and DR group for any of the spots.
DISCUSSION
The  results  of  the  current  study  demonstrated  that  AGE
modified proteins in DM tears are elevated in terms of the
number of AGE modified protein species and the degree of
modification  for  individual  proteins.  Glycation  (non-
enzymatic glycosylation) is a purely chemical reaction [20].
All proteins with free amino groups are subject to glycation
and high tear sugar concentrations as found in the tears of
diabetic  subjects  [18,19]  would  be  expected  to  result  in
increased  AGE  modified  proteins.  However,  the  protein
glycation process is slow [39] and tear turnover rate is fast
[40]. There is little known about the synthesis, storage and
secretion of tear proteins so information is absent about how
Figure 4. 2D western blotting images of AGE modified tear proteins from DR, DNR, and CTL samples and a Sypro ruby stained 2D gel image
of a tear sample.
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1581Figure  5.  Image  analysis  to  detect
expression differences of the individual
AGE modified protein spot between the
groups.  Only  the  spots  showing
significant differences were included in
the  figure  table.  No  significant
differences were detected between DNR
and DR groups.
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1582long tear proteins already exist in the body before they are
secreted into tear fluid. Some of the proteins in tears are
derived from blood [7], especially in the condition of diabetic
retinopathy [34,41], or released from ocular surface epithelial
cells [42]. It is likely that some proteins were glycated before
being secreted into tear fluid.
There  were  weak  correlations  between  tear  AGE
modified proteins and blood HbAc1 level or PBG. Previous
studies have reported that although tear glucose levels were
clearly increased in DM patients, the glucose levels in blood
and in tears did not always correlate [43]. This may be one
reason for the weak correlation.
There are AGE modified proteins in CTL tears, although
the amount was lower than in DM tears. As sugar exists in
normal tears [43] and glycation is a spontaneous chemical
reaction, the result is perhaps understandable. It is also well
known that increased glycation is part of the aging process
[44]. All the subjects in this study were elderly people and this
may be another reason that AGE modified proteins exist to
some extent in all their tears.
According to the spot density in the western blotting
membrane, the levels of some of the AGE modified proteins
change  significantly  between  the  groups,  such  as  spot  18
(Figure 5) among the three groups, spot 5 in DR comparing
with DNR or CTL. Identification of these spots by liquid
chromatography combined with mass spectrometry (LC-MS)
is underway and their potential as biomarkers to diagnose
diabetes and/or diabetic retinopathy warrantee further studies.
Studies have shown that AGE products are themselves
bioactive  [45,46].  Specific  receptors  have  been  found  for
AGE products [47,48] and the AGE modified proteins may
affect the ocular surface directly. It is also unknown whether
or not the modification of tear proteins, or the present of
glycation product, affects tear film stability.
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